Helius Medical Technologies (OTCMKTS:HSDT) released its quarterly earnings data on Thursday. The company reported ($0.19) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.04, Morningstar.com reports.
Helius Medical Technologies stock opened at $10.26 on Friday. Helius Medical Technologies has a 12 month low of $7.15 and a 12 month high of $14.50.
A hedge fund recently bought a new stake in Helius Medical Technologies stock. Bank of New York Mellon Corp bought a new position in shares of Helius Medical Technologies Inc (OTCMKTS:HSDT) in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 41,755 shares of the company’s stock, valued at approximately $397,000. Bank of New York Mellon Corp owned 0.18% of Helius Medical Technologies at the end of the most recent reporting period.
ILLEGAL ACTIVITY NOTICE: “Helius Medical Technologies (HSDT) Announces Quarterly Earnings Results” was originally reported by Stock Observer and is owned by of Stock Observer. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.thestockobserver.com/2018/11/10/helius-medical-technologies-hsdt-announces-quarterly-earnings-results.html.
About Helius Medical Technologies
Helius Medical Technologies, Inc is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company is engaged in the development of its product, the portable neuromodulation stimulator (PoNS) device.
Featured Story: What Is An Exchange-Traded Fund (ETF)?
Receive News & Ratings for Helius Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.